You are here

Ibrance Real World Insights [IRIS]

Last updated on October 9, 2019

FOR MORE INFORMATION
Study Location
Cheladv74, Inc.
New York, New York, 10017 United States
Contact
1-800-718-1021
ClinicalTrials.gov_Inqui[email protected]
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Malignant Neoplasm of Breast
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- ≥18 years old

- HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.

- Received palbociclib letrozole/aromatase inhibitor or palbociclib
fulvestrant in line with the licenced indication(s)

- No prior or current enrolment in an interventional clinical trial for ABC/MBC

- Minimum of three months of follow up data since palbociclib with fulvestrant
initiation, or minimum of six months of follow up data since palbociclib with
letrozole/aromatase inhibitor initiation (core medical record review)

- Minimum of three months of follow up data since palbociclib initiation (interim
medical record review)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- ≥18 years old

- HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.

- Received palbociclib letrozole/aromatase inhibitor or palbociclib
fulvestrant in line with the licenced indication(s)

- No prior or current enrolment in an interventional clinical trial for ABC/MBC

- Minimum of three months of follow up data since palbociclib with fulvestrant
initiation, or minimum of six months of follow up data since palbociclib with
letrozole/aromatase inhibitor initiation (core medical record review)

- Minimum of three months of follow up data since palbociclib initiation (interim
medical record review)

NCT03159195
Cheladv74
Not yet recruiting
Ibrance Real World Insights [IRIS]

NEED INFO?

Questions about a trial? Call or email to reach a Cheladv74 Clinical Trial Contact Center Representative

Cheladv74 Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Based on your search, you may also be interested in

Malignant Neoplasm of Breast
NCT03159195
Females
18+
Years
New York, New York
Descriptive Information
Brief TitleIbrance Real World Insights [IRIS]
Official TitleTREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS
Brief SummaryTo describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments in line with regional licensed indications in real world settings across multiple countries.
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationAdult female patients with HR+/HER2 advanced or metastatic breast cancer receiving palbociclib combination regimens as per the approved indication.
ConditionMalignant Neoplasm of Breast
InterventionDrug: Palbociclib
CDK 4/6 inhibitor for advanced/ metastatic breast cancer
Other Name: Ibrance
Study Groups/CohortsNot Provided
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusActive, not recruiting
Actual Enrollment
 (submitted: June 24, 2019)
700
Original Estimated Enrollment
 (submitted: May 17, 2017)
1200
Estimated Study Completion DateJune 3, 2020
Estimated Primary Completion DateJune 3, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

INCLUSION CRITERIA

  • ?18 years old
  • HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
  • Received palbociclib letrozole/aromatase inhibitor or palbociclib fulvestrant in line with the licenced indication(s)
  • No prior or current enrolment in an interventional clinical trial for ABC/MBC
  • Minimum of three months of follow up data since palbociclib with fulvestrant initiation, or minimum of six months of follow up data since palbociclib with letrozole/aromatase inhibitor initiation (core medical record review)
  • Minimum of three months of follow up data since palbociclib initiation (interim medical record review)
Sex/Gender
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Gender Eligibility Description:Female participants only
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesUnited States
Removed Location Countries  
 
Administrative Information
NCT NumberNCT03159195
Other Study ID NumbersA5481090
IRIS ( Other Identifier: Alias Study Number )
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Device Product:No
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Cheladv74 will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Cheladv74's data sharing criteria and process for requesting access can be found at: http://cheladv74.ru/science/clinical_trials/trial_data_and_results/da....
Responsible PartyCheladv74
Study SponsorCheladv74
CollaboratorsNot Provided
Investigators
Study Director:Cheladv74 CT.gov Call CenterCheladv74
PRS AccountCheladv74
Verification DateJuly 2019

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Cheladv74 Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now